Alexander Labrunerie & Co’s Novo Nordisk NVO Stock Holding History

Alexander Labrunerie & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$579K	Hold	12,077	–	–	0.2%	57
2026 Q1	$444K	Buy	12,077 +1,019	+9%	+$48.3K	0.17%	72
2025 Q4	$563K	Buy	11,058 +184	+2%	+$9.41K	0.2%	59
2025 Q3	$603K	Sell	10,874 -342	-3%	-$20K	0.22%	58
2025 Q2	$774K	Sell	11,216 -35	-0.3%	-$2.38K	0.32%	51
2025 Q1	$781K	Buy	11,251 +75	+0.7%	+$6.19K	0.34%	51
2024 Q4	$961K	Sell	11,176 -65	-0.6%	-$7.03K	0.42%	41
2024 Q3	$1.34M	Sell	11,241 -30	-0.3%	-$4K	0.61%	35
2024 Q2	$1.61M	Buy	11,271 +7	+0.1%	+$928	0.86%	28
2024 Q1	$1.45M	Buy	+11,264	New	+$1.34M	0.81%	28

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Alexander Labrunerie & Co's NVO Position: Q2 2026 in Review

Alexander Labrunerie & Co held its Novo Nordisk (NVO) position steady in Q2 2026 at 12,077 shares worth $579K. The position accounts for 0.2% of the portfolio, ranked #57.

Alexander Labrunerie & Co first reported a position in NVO in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.61M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Alexander Labrunerie & Co held 12,077 shares of Novo Nordisk worth $579K as of Q2 2026.
Alexander Labrunerie & Co left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.2% of Alexander Labrunerie & Co's portfolio in Q2 2026, its #57 holding.
Alexander Labrunerie & Co first reported a position in Novo Nordisk in Q1 2024 and has held it in 10 quarters since.
Alexander Labrunerie & Co's Novo Nordisk position peaked at $1.61M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Alexander Labrunerie & Co's 13F filing for Q2 2026, filed 3 Aug 2026.